Observational studyMedicine2025
Consideration of ledipasvir/sofosbuvir as an alternative to glecaprevir/pibrentasvir based upon on-treatment FIB-4 changes and sustained virologic response at 12 weeks in hepatitis C genotype 1 and 2 infections: A propensity score-matched study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited data are available on the effectiveness of ledipasvir/sofosbuvir (LDV/SOF) compared with glecaprevir/pibrentasvir (GLE/PIB) for the treatment of hepatitis C virus genotype 2 infection. The sustained virologic response at 12 weeks (SVR 12) rate and on-treatment fibrosis index-4 (FIB-4) change in HCV GT-1 and GT-2 patients receiving LDV/SOF and GLE/PIB treatments were compared using propensity score matching (PSM). The proportion of treatment-naïve patients in each group was 93.3% and 95.7% (P = .313), respectively. The overall SVR 12 rates of LDV/SOF for 12 weeks and GLE/PIB for 8 weeks were 99.3% (149/150) and 100% (232/232), respectively. We conducted 1:1 PSM to compare changes in the FIB-4 index before and after treatment. There was no significant difference in the on-treatment change of FIB-4 in the LDV/SOF and GLE/PIB group (3.0 ± 2.7 vs 2.8 ± 2.5, P = .518; 2.9 ± 2.5 vs 2.4 ± 3.4, P = .159). In addition, no significant difference in delta FIB-4 was shown between the groups in the PSM cohort (P = .939). Furthermore, on stratifying by FIB-4 subclassification, no significant differences in on-treatment delta FIB-4 were observed between the groups across the low, intermediate, and high FIB-4 subclassification (P = .909, 0.155, and 0.819, respectively). Fixed doses of LDV/SOF and GLE/PIB are effective for treating HCV GT-1 and GT-2 infections. There were no significant differences between the 2 regimens in on-treatment FIB-4 changes upon reaching SVR 12.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.